A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Terminated · Phase 1, Phase 2 · NCT03829501
Conditions: Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
At a glance
- Research payments reported, 2025
- $147,864
- U.S. investigators named
- 3
- Sites paid
- 4
- Planned or actual enrollment
- 222
About the trial
- Sponsor
- Kymab Limited (with Sanofi)
- Tested
- Alomfilimab (drug), Atezolizumab (drug)
- Dates
- Started 2019-01-28; completion 2024-10-03
- Results posted
- Yes
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their disease, or they have exhausted all such available options in each indication and therefore will be patients for whom a clinical trial is appropriate.
From ClinicalTrials.gov, last updated 2025-04-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $147,864 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- David R. Spigel, M.D. Medical Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute $134,812
- Sarah Cannon Research Inst Llc $9,452
- Sarah Cannon Research Institution Llc $2,100
- Yale University Keck Biotechnology Laboratory $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.